Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients-Reference-Cited by-同舟云学术

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients

Published:2007-02-17 Issue:9 Volume:26 Page:1459-1465
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Reinders Mattheus K.,van Roon Eric N.,Houtman Pieternella M.,Brouwers Jacobus R. B. J.,Jansen Tim L. Th. A.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-006-0528-3

Reference31 articles.

1. Jansen TL, Reinders MK, van Roon EN et al (2004) Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol 22:651

2. Van der Klauw MM, Houtman PM, Stricker BH et al (1994) Hepatic injury caused by benzbromarone. J Hepatol 20:376–379

3. Wagayama H, Shiraki K, Sugimoto K et al (2000) Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 32:874

4. Arai M, Yokosuka O, Fujiwara K et al (2002) Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 17:625–626

5. Masbernard A, Giudicelli CP (1981) Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 59:701–706

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of gout treatments in people with renal impairment;Exploration of Musculoskeletal Diseases;2024-09-02

2. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease;Cells;2024-03-04

3. Superiority of low dose benzbromarone add‐on to low dose febuxostat compared to febuxostat monotherapy in gout with combined‐type hyperuricemia;Arthritis Care & Research;2023-12-21

4. hURAT1Transgenic Mouse Model for Evaluating Targeted Urate-Lowering Agents;2023-11-17

5. Lessons to be learned from real life data from 98 gout patients using benzbromarone;Exploration of Musculoskeletal Diseases;2023-10-30